Regeneron Pharmaceuticals REGN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $14.34B+1.0% | $14.2B+8.3% | $13.12B+7.8% | $12.17B-24.3% | ||
| —— | —— | —— | —— | ||
| $5.85B+14.0% | $5.13B+15.6% | $4.44B+23.6% | $3.59B+25.6% | ||
| $2.7B-8.6% | $2.95B+12.3% | $2.63B+24.4% | $2.12B+15.9% | ||
| $10.77B+5.4% | $10.21B+12.6% | $9.07B+22.0% | $7.43B+4.3% | ||
| $3.58B-10.3% | $3.99B-1.4% | $4.05B-14.6% | $4.74B-47.0% | ||
| 24.9%-3.2pp | 28.1%-2.8pp | 30.9%-8.1pp | 38.9%-16.7pp | ||
| $43.8M-20.7% | $55.2M-24.4% | $73M+22.9% | $59.4M+3.7% | ||
| $1.65B+101% | $821.3M+440% | $152.2M+26.9% | $119.9M— | ||
| $5.23B+9.4% | $4.78B+13.8% | $4.2B-13.6% | $4.86B-47.9% | ||
| $725.8M+97.6% | $367.3M+42.5% | $257.7M-50.5% | $520.4M-58.4% | ||
| $4.5B+2.1% | $4.41B+11.6% | $3.95B-8.9% | $4.34B-46.3% | ||
| 31.4%+0.3pp | 31.1%+0.9pp | 30.1%-5.5pp | 35.6%-14.6pp | ||
| $41.57+8.5% | $38.33+10.3% | $34.76-9.1% | $38.23-47.0% | ||
| $4.12B-7.9% | $4.47B+0.1% | $4.47B-12.1% | $5.08B-45.0% | ||
| 28.7%-2.8pp | 31.5%-2.6pp | 34.1%-7.7pp | 41.7%-15.7pp | ||
| $3.58B-10.3% | $3.99B-1.4% | $4.05B-14.6% | $4.74B-47.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $14.9B in revenue over the trailing twelve months, up 5.9% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.4B in net income over the trailing twelve months, a 29.6% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 93.9% and operating margin is 24.3%, with a 29.6% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $41.05.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
